485 patents
Page 21 of 25
Utility
Crystalline Forms of a Brutons Tyrosine Kinase Inhibitor
22 Jul 20
Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof.
Norbert Purro, Mark S. Smyth, Erick Goldman, David D. Wirth
Filed: 18 Mar 20
Utility
Pharmaceutical Compositions and Methods of Use Thereof to Treat Pancreatic Enzyme Insufficiency
22 Jul 20
The present disclosure relates to pharmaceutical compositions comprising enzymes or enzyme mixtures having lipolytic and other optional other activities and methods of use thereof to treat exocrine pancreatic insufficiency.
Jerry A. HALL, Pedro Quintana DIAZ, Shufang LlU, Peter GREGORY, Beate JOHANNWILLE, Suntje SANDER-STRUCKMEIER, Hans-Friedrich KOCH
Filed: 17 Mar 20
Utility
Apoptosis Inducing Agents for the Treatment of Cancer and Immune and Autoimmune Diseases
22 Jul 20
Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
Milan Bruncko, Hong Ding, George A. Doherty, Steven W. Elmore, Lisa A. Hasvold, Laura Hexamer, Aaron R. Kunzer, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Gary T. Wang, Le Wang, Xilu Wang, Michael D. Wendt, Robert Mantei, Todd M. Hansen
Filed: 29 Aug 19
Utility
Methods for Treating HCV
15 Jul 20
The present invention features interferon-free therapies for the treatment of HCV.
Christine Collins, Bo Fu, Abhishek Gulati, Jens Kort, Matthew Kosloski, Yang Lei, Chih-Wei Lin, Ran Liu, Federico Mensa, Iok Chan Ng, Tami Pilot-Matias, David Pugatch, Nancy S. Shulman, Roger Trinh, Rolando M. Viani, Stanley Wang, Zhenzhen Zhang
Filed: 19 Jul 18
Utility
Methods of Treatment Using Selective BCL-2 Inhibitors
15 Jul 20
This invention pertains to methods of treating systemic lupus erythematosus and Sjogren's Syndrome with compounds that selectively inhibit the activity of Bcl-2 anti-apoptotic proteins.
Steven Elmore, Andrew Souers, Lichun Wang, Tariq Ghayur, Stuart J. Perper
Filed: 16 May 19
Utility
Crystalline Forms of a Brutons Tyrosine Kinase Inhibitor
15 Jul 20
Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof.
Norbert Purro, Mark S. Smyth, Erick Goldman, David D. Wirth
Filed: 31 Mar 20
Utility
ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
8 Jul 20
The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.
Christian B. ALLAN, Louie NAUMOVSKI, Edward B. REILLY
Filed: 16 Jan 20
Utility
Methods of treating and preventing graft versus host disease
29 Jun 20
Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors.
John C. Byrd, Jason A. Dubovsky, Natarajan Muthusamy, Amy J. Johnson, David Miklos
Filed: 24 Sep 19
Utility
Enzymatic processes for the preparation of (±)-2-(difluoromethyl)-1-(alkoxycarbonyl)-cyclopropanecarboxylic acid and (±)-2-(vinyl)-1-(alkoxycarbonyl)-cyclopropanecarboxylic acid
22 Jun 20
Disclosed are methods of synthesizing racemic 2-(difluoromethyl)-1-(alkoxycarbonyl)-cyclopropanecarboxylic acids and 2-(vinyl)-1-(alkoxycarbonyl)-cyclopropanecarboxylic acids and their salts, such as the dicyclohexylamine salt.
Michael J. Abrahamson, Sanjay R. Chemburkar, Angelica B. Kielbus, Russell D. Cink
Filed: 31 Jan 18
Utility
Container Cap and Method of Piercing a Seal Covering an Opening of a Container
17 Jun 20
A container cap (100) configured to couple to an access opening of a container, and the access opening having a seal configured to cover the access opening.
Joy Elizabeth Borgardt, James J. Hughes, Ted Klikuszowian, Todd Marshall, Marc Plew, Kelsey M. Coffey, Scott L. Fisher, Jason A. Rowe
Filed: 15 Apr 18
Utility
Anti-egfr Antibody Drug Conjugates (Adc) and Uses Thereof
17 Jun 20
Provided herein are antibody-drug conjugates that bind EGFR, in particular human EGFR, their methods of making, and their uses to treat patients having cancer.
Edward Reilly, Mark Anderson
Filed: 3 Sep 18
Utility
Methods of administering elagolix
15 Jun 20
The present disclosure relates to the use of GnRH receptor antagonists used in the treatment of endometriosis or uterine fibroids.
Sandra L. Goss, Cheri E. Klein, Juki Wing-Keung Ng, Ahmed Salem
Filed: 19 Dec 19
Utility
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
10 Jun 20
The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Ayman ALLIAN, Jayanthy JAYANTH, Ben KLÜNDER, Mohamed-Eslam F. MOHAMED, Ahmed A. OTHMAN, Patrick J. MARROUM, Peter T. MAYER
Filed: 10 Feb 20
Utility
Anti SEZ6 Antibodies and Methods of Use
10 Jun 20
Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, ROBERT A. STULL, MICHAEL TORGOV, HUI SHAO, DAVID LIU
Filed: 11 Dec 19
Utility
Methods of Administering Anti-tnfalpha Antibodies
10 Jun 20
Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed.
Steven A. FISCHKOFF, Joachim KEMPENI, Roberta WEISS
Filed: 6 Feb 20
Utility
ANTI-OX40 Antibodies and Their Uses
10 Jun 20
The present disclosure provides novel anti-OX40 antibodies, compositions including the antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
Fiona A. HARDING
Filed: 19 Feb 20
Utility
Medicine container, method of assembling the container, and method of dispensing the medicine from the container
8 Jun 20
A child-resistant medication container assembly and method of dispensing the medication from the container assembly.
Guy Upchurch, John G. Finch
Filed: 4 Jan 16
Utility
Macrocyclic MCL-1 inhibitors and methods of use
8 Jun 20
Andrew S. Judd, Aaron R. Kunzer, Chunqiu Lai, Andrew J. Souers, Zhi-Fu Tao, Anthony Mastracchio, Xilu Wang, Cheng Ji, Michael D. Wendt, Xiaohong Song, George A. Doherty, Thomas D. Penning
Filed: 14 Aug 18
Utility
Glucocorticoid receptor agonist and immunoconjugates thereof
1 Jun 20
Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same, e.g., to treat autoimmune or inflammatory diseases.
Michael J. McPherson, Adrian D. Hobson, Martin E. Hayes, Christopher C. Marvin, Diana Schmidt, Wendy Waegell, Christian Goess, Jason Z. Oh, Axel Hernandez, Jr., John T. Randolph
Filed: 9 May 19
Utility
Use of Inhibitors of Brutons Tyrosine Kinase (BTK)
27 May 20
Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
Joseph J. Buggy, Gwen Fyfe, Lee Honigberg, David J. Loury
Filed: 20 Jan 20